RNA, U6 small nuclear 431, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6-431P profile across patient tissues and cancer cell-line models. RNU6-431P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, RNU6-431P is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RNU6-431P RNA expression shows 15,619 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight THCA, KIRC, and DLBC as cancer lineages where RNU6-431P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-431P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-431P survival associations across molecular data types. RNU6-431P RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-431P RNA expression–survival associations across cancer types. High RNU6-431P expression shows unfavorable associations in THCA, COAD, CHOL and BLCA, but favorable associations in UCS and LAML. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for RNU6-431P RNA expression.
This table summarizes RNU6-431P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-431P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-431P shows lower tumor expression in THCA and higher tumor expression in KIRC, LUSC, HNSC, LIHC and CHOL. The KIRC box plot shows higher RNU6-431P RNA expression in tumor versus normal tissue (log2 FC = +0.507, t-test p < 0.001).
This table shows molecular features associated with RNU6-431P in patient tissues and cancer cell lines. In patient samples, RNU6-431P shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
